 Monoclonal Gammopathy of Undetermined Significance
"Monoclonal Gammopathy of Undetermined Significance" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.
| Descriptor ID |
D008998
|
| MeSH Number(s) |
C15.378.147.542.640 C20.683.460.640 C20.683.780.640
|
| Concept/Terms |
Monoclonal Gammopathy of Undetermined Significance- Monoclonal Gammopathy of Undetermined Significance
- Monoclonal Gammapathies, Benign
- Benign Monoclonal Gammapathies
- Benign Monoclonal Gammapathy
- Gammapathies, Benign Monoclonal
- Gammapathy, Benign Monoclonal
- Monoclonal Gammapathy, Benign
- Monoclonal Gammopathies, Benign
- Benign Monoclonal Gammopathies
- Benign Monoclonal Gammopathy
- Gammopathies, Benign Monoclonal
- Gammopathy, Benign Monoclonal
- Monoclonal Gammopathy, Benign
- Monoclonal Gammapathy of Undetermined Significance
|
Below are MeSH descriptors whose meaning is more general than "Monoclonal Gammopathy of Undetermined Significance".
Below are MeSH descriptors whose meaning is more specific than "Monoclonal Gammopathy of Undetermined Significance".
This graph shows the total number of publications written about "Monoclonal Gammopathy of Undetermined Significance" by people in UAMS Profiles by year, and whether "Monoclonal Gammopathy of Undetermined Significance" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 1 | 2 | | 2023 | 2 | 0 | 2 | | 2022 | 3 | 0 | 3 | | 2021 | 2 | 0 | 2 | | 2020 | 2 | 0 | 2 | | 2018 | 1 | 1 | 2 | | 2017 | 2 | 2 | 4 | | 2016 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2013 | 1 | 1 | 2 | | 2010 | 3 | 1 | 4 | | 2009 | 1 | 0 | 1 | | 2006 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Monoclonal Gammopathy of Undetermined Significance" by people in Profiles over the past ten years.
-
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024 11 06; 14(1):194.
-
Joseph JM, Hillengass J, Tang L, Lesokhin AM, Landgren O, Usmani SZ, Moysich KB, McCann SE, Shah UA. Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population. Blood Adv. 2024 02 13; 8(3):538-548.
-
Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70.
-
Roy Choudhury S, Byrum SD, Alkam D, Ashby C, Zhan F, Tackett AJ, Van Rhee F. Expression of integrin ?-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clin Epigenetics. 2023 02 04; 15(1):18.
-
Khalili P, Maddah R, Maleknia M, Shateri Amiri B, Forouzani F, Hasanvand A, Rezaeeyan H. Evaluation of Genes and Molecular Pathways Involved in the Progression of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma: A Systems Biology Approach. Mol Biotechnol. 2023 Aug; 65(8):1275-1286.
-
Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies F, Raab MS, Morgan G, Weinhold N. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022 11 22; 6(22):5873-5883.
-
Steinhardt M, Kort?m M, Einsele H, Rasche L. [Monoclonal gammopathy of (un)known significance]. Dtsch Med Wochenschr. 2022 06; 147(11):675-682.
-
Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021; 12:667054.
-
Oben B, Froyen G, Maclachlan KH, Leongamornlert D, Abascal F, Zheng-Lin B, Yellapantula V, Derkach A, Geerdens E, Diamond BT, Arijs I, Maes B, Vanhees K, Hultcrantz M, Manasanch EE, Kazandjian D, Lesokhin A, Dogan A, Zhang Y, Mikulasova A, Walker B, Morgan G, Campbell PJ, Landgren O, Rummens JL, Bolli N, Maura F. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun. 2021 03 25; 12(1):1861.
-
Abell K, Chadwell SE, Burrow TA, Becker APP, Bailey L, Steele P, Zhang X, Islas-Ohlmayer M, Bittencourt R, Schwartz IVD, Prada CE. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States. Am J Med Genet C Semin Med Genet. 2020 12; 184(4):1052-1059.
-
Han JH, Wang JN, Zhang YL, Cao XX, Zhou DB, Xu TD, Su W, Li J. Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China. Blood Cancer J. 2020 03 09; 10(3):34.
-
Tomasson MH, Ali M, De Oliveira V, Xiao Q, Jethava Y, Zhan F, Fitzsimmons AM, Bates ML. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. Int J Mol Sci. 2018 Nov 16; 19(11).
-
Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clin Cancer Res. 2018 06 15; 24(12):2913-2919.
-
Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Cairns DA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematol. 2017 Dec; 4(12):e584-e594.
-
Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT. Active multiple myeloma suppresses and typically eliminates coexisting MGUS. Br J Cancer. 2017 Sep 05; 117(6):835-839.
-
Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017 09; 102(9):1617-1625.
-
Cao XX, Meng Q, Cai H, He TH, Zhang CL, Su W, Sun J, Li Y, Xu W, Zhou DB, Li J. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Ann Hematol. 2017 Jun; 96(6):971-976.
-
Papanikolaou X, Rosenthal A, Dhodapkar M, Epstein J, Khan R, van Rhee F, Jethava Y, Waheed S, Zangari M, Hoering A, Crowley J, Alapat D, Davies F, Morgan G, Barlogie B. Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120). Blood Cancer J. 2016 Mar 25; 6:e410.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|